The 2025 market analysis identifies Oral Chemotherapy as the fastest-growing route of administration, now capturing over 56% of the market share. The convenience of at-home treatment and the development of "Sustained-Release" pills have led to high patient preference and improved adherence rates. Recent 2025 approvals, such as the oral tyrosine kinase inhibitor Zongertinib, offer alternative...